Get the Stockscreener App
1.41
1.42%
-0.00
Revelation Biosciences Inc stock is traded at $1.41, with a volume of 14,821.
It is down -1.42% in the last 24 hours and down -63.38% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
See More
Previous Close:
$1.41
Open:
$1.41
24h Volume:
14,821
Relative Volume:
0.03
Market Cap:
$3.67M
Revenue:
-
Net Income/Loss:
$-15.52M
P/E Ratio:
-0.0759
EPS:
-18.58
Net Cash Flow:
$-16.61M
1W Performance:
-4.79%
1M Performance:
-63.38%
6M Performance:
-86.26%
1Y Performance:
-92.14%
1-Day Range:
$1.38
$1.43
1-Week Range:
$1.35
$1.56
52-Week Range:
$1.35
$18.16
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
1.40 | 3.70M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.60 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
777.14 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.16 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.32 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.00 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Revelation Biosciences Inc Stock (REVB) Latest News
Energy Moves: Is Revelation Biosciences Inc Equity Warrant backed by strong institutional buying2025 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Portfolio Shifts: How does Revelation Biosciences Inc compare to its peersWeekly Market Outlook & Entry and Exit Point Strategies - baoquankhu1.vn
Bearish Setup: Whats the profit margin of Revelation Biosciences Inc Equity Warrant2025 Key Lessons & Real-Time Volume Spike Alerts - baoquankhu1.vn
Analysis Recap: Is FEMYs ROIC above industry averageDividend Hike & Consistent Income Trade Recommendations - baoquankhu1.vn
How does Revelation Biosciences Inc. compare to its peersJuly 2025 Review & Fast Gain Stock Trading Tips - mfd.ru
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - BlueRidgeNow.com
Is Revelation Biosciences Inc. stock positioned for digital transformationTrade Risk Assessment & AI Forecasted Entry/Exit Points - mfd.ru
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Columbia Daily Tribune
What makes Revelation Biosciences Inc. stock attractive todayJuly 2025 Big Picture & High Return Trade Guides - mfd.ru
Why retail investors pile into Revelation Biosciences Inc. stockInsider Selling & Weekly Setup with ROI Potential - mfd.ru
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - Lubbock Avalanche-Journal
Can Revelation Biosciences Inc. deliver alphaJuly 2025 Reactions & Reliable Momentum Entry Alerts - mfd.ru
Will Revelation Biosciences Inc. stock gain from lower inflation2025 Key Highlights & Daily Market Momentum Tracking - mfd.ru
Breakout Zone: What are the risks of holding Revelation Biosciences IncJuly 2025 Fed Impact & Fast Entry Momentum Alerts - baoquankhu1.vn
Revelation Biosciences (REVB) Price Target Increased by 300.00% to 86.70 - Nasdaq
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Victorville Daily Press
Fundamentals Check: What is Graf Global Corp Debt Equity Composite Unitss valuation compared to sectorJuly 2025 Breakouts & AI Driven Price Forecasts - baoquankhu1.vn
Buyback Watch: Is ETHE trading at a discountJuly 2025 Market Mood & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Revelation Biosciences Inc. expand into new marketsPortfolio Value Report & Daily Market Momentum Tracking - mfd.ru
Is Revelation Biosciences Inc. Equity Warrant backed by strong institutional buyingWeekly Market Summary & Weekly Return Optimization Alerts - mfd.ru
Revelation Biosciences Raises Capital via Warrant Inducement - TipRanks
Revelation Biosciences Signs Multiple Material Agreements - TradingView
REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year - Asianet Newsable
Will PSIG stock benefit from M AWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
US Market Recap: Whats the beta of Revelation Biosciences Inc stock2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):